Literature DB >> 20346682

Ircinialactams: subunit-selective glycine receptor modulators from Australian sponges of the family Irciniidae.

Walter Balansa1, Robiul Islam, Frank Fontaine, Andrew M Piggott, Hua Zhang, Timothy I Webb, Daniel F Gilbert, Joseph W Lynch, Robert J Capon.   

Abstract

Screening an extract library of >2500 southern Australian and Antarctic marine invertebrates and algae for modulators of glycine receptor (GlyR) chloride channels identified three Irciniidae sponges that yielded new examples of a rare class of glycinyl lactam sesterterpene, ircinialactam A, 8-hydroxyircinialactam A, 8-hydroxyircinialactam B, ircinialactam C, ent-ircinialactam C and ircinialactam D. Structure-activity relationship (SAR) investigations revealed a new pharmacophore with potent and subunit selective modulatory properties against alpha1 and alpha3 GlyR isoforms. Such GlyR modulators have potential application as pharmacological tools, and as leads for the development of GlyR targeting therapeutics to treat chronic inflammatory pain, epilepsy, spasticity and hyperekplexia. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346682     DOI: 10.1016/j.bmc.2010.03.002

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  17 in total

1.  Proliferation characteristics of cells cultured under periodic versus static conditions.

Authors:  Daniel F Gilbert; Sepideh Abolpour Mofrad; Oliver Friedrich; Joachim Wiest
Journal:  Cytotechnology       Date:  2018-12-04       Impact factor: 2.058

Review 2.  Glycine receptors and glycine transporters: targets for novel analgesics?

Authors:  Hanns Ulrich Zeilhofer; Mario A Acuña; Jacinthe Gingras; Gonzalo E Yévenes
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

3.  Identification of the First Marine-Derived Opioid Receptor "Balanced" Agonist with a Signaling Profile That Resembles the Endorphins.

Authors:  Tyler A Johnson; Laura Milan-Lobo; Tao Che; Madeline Ferwerda; Eptisam Lambu; Nicole L McIntosh; Fei Li; Li He; Nicholas Lorig-Roach; Phillip Crews; Jennifer L Whistler
Journal:  ACS Chem Neurosci       Date:  2016-11-22       Impact factor: 4.418

4.  Phosphorylation of α3 glycine receptors induces a conformational change in the glycine-binding site.

Authors:  Lu Han; Sahil Talwar; Qian Wang; Qiang Shan; Joseph W Lynch
Journal:  ACS Chem Neurosci       Date:  2013-07-18       Impact factor: 4.418

Review 5.  Recent progress in neuroactive marine natural products.

Authors:  Ryuichi Sakai; Geoffrey T Swanson
Journal:  Nat Prod Rep       Date:  2014-01-17       Impact factor: 13.423

6.  State-of-the-Art Automated Patch Clamp Devices: Heat Activation, Action Potentials, and High Throughput in Ion Channel Screening.

Authors:  Sonja Stoelzle; Alison Obergrussberger; Andrea Brüggemann; Claudia Haarmann; Michael George; Ralf Kettenhofen; Niels Fertig
Journal:  Front Pharmacol       Date:  2011-11-24       Impact factor: 5.810

Review 7.  Change the channel: CysLoop receptor antagonists from nature.

Authors:  Guanghu Tong; Meghan A Baker; Ryan A Shenvi
Journal:  Pest Manag Sci       Date:  2020-11-22       Impact factor: 4.462

Review 8.  Marine pharmacology in 2009-2011: marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Orazio Taglialatela-Scafati; Nobuhiro Fusetani
Journal:  Mar Drugs       Date:  2013-07-16       Impact factor: 5.118

9.  Bioactive marine drugs and marine biomaterials for brain diseases.

Authors:  Clara Grosso; Patrícia Valentão; Federico Ferreres; Paula B Andrade
Journal:  Mar Drugs       Date:  2014-05-02       Impact factor: 5.118

Review 10.  Defects of the Glycinergic Synapse in Zebrafish.

Authors:  Kazutoyo Ogino; Hiromi Hirata
Journal:  Front Mol Neurosci       Date:  2016-06-29       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.